We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+2.26%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
-$221M
Cap. Flow
-$84.5M
Cap. Flow %
-3.86%
Top 10 Hldgs %
70.17%
Holding
54
New
4
Increased
10
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$49.7M
2
DYN icon
Dyne Therapeutics
DYN
+$20.6M
3
RNAM
Avidity Biosciences
RNAM
+$16.4M
4
ZLAB icon
Zai Lab
ZLAB
+$10.8M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$10.6M

Top Sells

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$66.1M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$33.9M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$21.7M
4
ANAB icon
AnaptysBio
ANAB
+$20.8M
5
KRYS icon
Krystal Biotech
KRYS
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$314M
– –
-1,176,735
Closed -$4.85M
ETNB
52
DELISTED
89bio
ETNB
– –
-1,000,000
Closed -$7.82M
EWTX icon
53
Edgewise Therapeutics
EWTX
$4.28B
– –
-1,271,245
Closed -$33.9M
PLRX icon
54
Pliant Therapeutics
PLRX
$71.2M
– –
-1,120,803
Closed -$14.8M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2025 Portfolio in Review

As of Q1 2025, Frazier Life Sciences Management held 54 positions worth $2.19B, down 9.2% from $2.41B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Frazier Life Sciences Management withdrew a net $84.5M in Q1 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $33.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Maze Therapeutics worth $45.5M.

  • Frazier Life Sciences Management's largest Q1 2025 buy was Maze Therapeutics: 4,129,001 shares worth $45.5M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2025, an estimated $10.6M increase.
  • Frazier Life Sciences Management's biggest Q1 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $66.1M.
  • Frazier Life Sciences Management fully exited Edgewise Therapeutics in Q1 2025, selling an estimated $33.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 70% of its $2.19B portfolio in Q1 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 7 in Q1 2025.
  • Frazier Life Sciences Management's portfolio value fell 9.2% quarter-over-quarter to $2.19B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.